Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:KRYS NASDAQ:ONC NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.90-4.2%$94.46$79.52▼$124.00$23.24B1.331.06 million shs594,328 shsKRYSKrystal Biotech$304.80-1.4%$277.59$124.00▼$319.48$9.01B0.53290,229 shs94,640 shsONCBeOne Medicines$275.27-4.4%$302.03$239.25▼$385.22$30.20B0.49250,836 shs121,571 shsRVMDRevolution Medicines$163.09+3.6%$129.46$34.00▼$164.30$34.66B1.43.36 million shs4.04 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+4.14%-7.25%-10.73%+0.25%KRYSKrystal Biotech0.00%+3.20%+17.83%+19.40%+143.22%ONCBeOne Medicines0.00%-7.20%-2.49%-8.41%+17.02%RVMDRevolution Medicines0.00%+3.91%+9.27%+54.97%+293.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.90-4.2%$94.46$79.52▼$124.00$23.24B1.331.06 million shs594,328 shsKRYSKrystal Biotech$304.80-1.4%$277.59$124.00▼$319.48$9.01B0.53290,229 shs94,640 shsONCBeOne Medicines$275.27-4.4%$302.03$239.25▼$385.22$30.20B0.49250,836 shs121,571 shsRVMDRevolution Medicines$163.09+3.6%$129.46$34.00▼$164.30$34.66B1.43.36 million shs4.04 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+4.14%-7.25%-10.73%+0.25%KRYSKrystal Biotech0.00%+3.20%+17.83%+19.40%+143.22%ONCBeOne Medicines0.00%-7.20%-2.49%-8.41%+17.02%RVMDRevolution Medicines0.00%+3.91%+9.27%+54.97%+293.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.5641.44% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.116.41% UpsideONCBeOne Medicines 2.80Moderate Buy$389.1540.59% UpsideRVMDRevolution Medicines 3.00Buy$116.00-28.74% DownsideCurrent Analyst Ratings BreakdownLatest KRYS, ONC, RVMD, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026RVMDRevolution Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/1/2026RVMDRevolution Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$165.00 ➝ $195.006/1/2026BNTXBioNTech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/27/2026BNTXBioNTech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$117.00 ➝ $135.005/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$151.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$96.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026RVMDRevolution Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B7.14$1.27 per share71.87$96.59 per share0.95KRYSKrystal Biotech$389.13M23.07$7.19 per share42.39$42.06 per share7.24ONCBeOne Medicines$5.34B5.68$3.76 per share73.67$39.77 per share6.96RVMDRevolution Medicines$11.58M2,988.57N/AN/A$8.44 per share19.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.5828.95N/A53.92%19.25%17.62%8/3/2026 (Estimated)ONCBeOne Medicines$286.93M$4.4762.0626.69N/A8.94%12.06%6.69%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)Latest KRYS, ONC, RVMD, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74KRYSKrystal BiotechN/A9.469.06ONCBeOne Medicines0.203.643.27RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%KRYSKrystal Biotech86.29%ONCBeOne Medicines48.55%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%KRYSKrystal Biotech13.10%ONCBeOne Medicines6.19%RVMDRevolution Medicines7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ARVMDRevolution Medicines250212.60 million196.44 millionOptionableKRYS, ONC, RVMD, and BNTX HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript1 hour ago | seekingalpha.comRVMD Stock Rises on Detailed Results From Pancreatic Cancer Study3 hours ago | zacks.comRevolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case4 hours ago | gurufocus.comMUFG Securities EMEA plc Buys New Holdings in Revolution Medicines, Inc. $RVMDJune 1 at 5:49 AM | marketbeat.comRVMD stock jumps overnight: New drug heads to FDA after 'unprecedented' 1-year survival win in pancreatic cancerMay 31 at 11:10 PM | msn.comRevolution Medicines Reports Breakthrough Phase 3 Results for Daraxonrasib in Metastatic Pancreatic CancerMay 31 at 8:11 AM | quiverquant.comQRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic CancerMay 31 at 8:06 AM | globenewswire.comZweig DiMenna Associates LLC Purchases New Position in Revolution Medicines, Inc. $RVMDMay 30 at 7:27 AM | marketbeat.comSBI Okasan Asset Management Co.Ltd. Invests $797,000 in Revolution Medicines, Inc. $RVMDMay 30 at 6:01 AM | marketbeat.comJefferies Financial Group Inc. Acquires 1,128,195 Shares of Revolution Medicines, Inc. $RVMDMay 24, 2026 | marketbeat.comCatalyst Funds Management Pty Ltd Purchases 13,400 Shares of Revolution Medicines, Inc. $RVMDMay 24, 2026 | marketbeat.comBernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendationMay 23, 2026 | msn.comRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO PresentationMay 21, 2026 | globenewswire.comEagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMDMay 21, 2026 | marketbeat.comProfund Advisors LLC Has $2.15 Million Stock Holdings in Revolution Medicines, Inc. $RVMDMay 20, 2026 | marketbeat.comNeedham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider LossMay 20, 2026 | insidermonkey.comGraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum StocksMay 19, 2026 | benzinga.comAssessing Revolution Medicines (RVMD) Valuation After A Powerful Multi Year Shareholder Return RunMay 17, 2026 | finance.yahoo.comCancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: ReportMay 15, 2026 | benzinga.comAIHC Capital Management Ltd Acquires New Holdings in Revolution Medicines, Inc. $RVMDMay 15, 2026 | marketbeat.comRevolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside PotentialMay 14, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBerkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 20263 Emerging Markets ETFs to Maximize Exposure to High-Potential CountriesBy Nathan Reiff | May 4, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and BookingBy Jessica Mitacek | May 7, 2026KRYS, ONC, RVMD, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$91.90 -4.05 (-4.22%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Krystal Biotech NASDAQ:KRYS$304.80 -4.23 (-1.37%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.BeOne Medicines NASDAQ:ONC$275.27 -12.65 (-4.39%) As of 02:06 PM Eastern This is a fair market value price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Revolution Medicines NASDAQ:RVMD$163.09 +5.61 (+3.56%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
